GICS Sector : Healthcare
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system.The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts
Dec -01
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Nov -25
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
Nov -19
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Nov -05
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Nov -05
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Nov -03
Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs Transcript
Oct -31
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Oct -30
Foghorn Therapeutics Inc.'s medicines exhibit 9.27% growth driven by increasing demand for precision medicine, advancements in gene regulation, and rising investments in oncology research. Additionally, strategic partnerships, expanded product pipelines, and favorable regulatory environments contribute to this growth.
Foghorn Therapeutics' gene regulation therapies are designed to selectively modulate gene expression to treat a range of diseases, including cancer and genetic disorders.
Foghorn's chromatin regulatory therapies target the chromatin regulatory system to modulate gene expression and treat diseases such as cancer and neurological disorders.
Foghorn's epigenetic therapies focus on modifying epigenetic marks to treat diseases such as cancer, neurological disorders, and rare genetic disorders.
Foghorn's gene editing therapies utilize CRISPR-Cas9 and other gene editing technologies to treat genetic diseases and disorders.
Foghorn Therapeutics Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.
Foghorn Therapeutics Inc. has a low bargaining power of customers due to the lack of concentration of buyers in the market.
Foghorn Therapeutics Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market.
Foghorn Therapeutics Inc. has a high threat of new entrants due to the attractiveness of the market and the ease of entry.
Foghorn Therapeutics Inc. operates in a highly competitive market with many established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | -140.34% |
| Debt Cost | 3.95% |
| Equity Weight | 240.34% |
| Equity Cost | 19.71% |
| WACC | 41.83% |
| Leverage | -58.39% |
Value: 7.8
Growth: 3.3
Quality: 4.3
Yield: 0.0
Momentum: 9.5
Volatility: 1.0
1-Year Total Return ->
Value: 7.8
Growth: 4.8
Quality: 3.0
Yield: 0.0
Momentum: 6.0
Volatility: 3.0
1-Year Total Return ->
Value: 8.0
Growth: 5.4
Quality: 4.5
Yield: 0.0
Momentum: 3.5
Volatility: 2.0
1-Year Total Return ->
Value: 6.0
Growth: 2.6
Quality: 2.6
Yield: 0.0
Momentum: 9.5
Volatility: 2.3
1-Year Total Return ->
Value: 8.0
Growth: 5.4
Quality: 6.0
Yield: 0.0
Momentum: 2.0
Volatility: 1.3
1-Year Total Return ->
Value: 9.4
Growth: 2.3
Quality: 4.9
Yield: 0.0
Momentum: 0.5
Volatility: 0.7
1-Year Total Return ->